Key words: chronic haemodialysis; HCV RNA; hepatitis C virus; viraemia Background. Immunologic alterations have been reported in chronic haemodialysis (HD) patients. Some HD patients may have, therefore, an inability to produce detectable amounts of serum antibodies to Introduction hepatitis C virus (anti-HCV ). Previous studies have shown the presence of HCV viraemia in anti-HCVPatients on haemodialysis (HD) are considered to be negative HD patients (ranging from 1 to 15%). a high risk group for contracting hepatitis C virus However, the universal epidemiologic impact of these (HCV ) infection [1] [2] [3] . The prevalence of antibodies cases remains uncertain since there are conflicting to HCV (anti-HCV ) in HD patients ranges worldwide results. In this context, we conducted a study in an from 1% in the UK to 62% in Portugal [1] [2] [3] . This attempt to investigate the presence of HCV viraemia variability appears to be dependent on the particular among anti-HCV-negative HD patients in a wellcountry, the strategy of precautions in various dialysis defined geographic area of the northwestern part of centres, the presence of other viral markers and the Greece.
HCV RNA in anti-HCV negative haemodialysis patients 1805 for anti-HCV in blood banks). The clinical and demographic Discussion characteristics of the patients are shown in Table 1 . All of them were repeatedly negative by two commercially available Contrary to what has been observed by others [11] [12] [13] [14] , third generation enzyme immunoassays for at least 1 year this study failed to confirm the presence of viraemia before the beginning of the study (Murex Diagnostics Ltd, in anti-HCV-negative HD patients. It is interesting to Central Road Temple Hill, UK, and Abbott Laboratories, notify that the absence of HCV viraemia in this study Wiesbaden Germany). These immunoassays utilize microplate wells coated with a combination of HCV antigens from was observed even among the anti-HCV-negative HD the putative core (structural ), protease/helicase [(NS3, non-patients who started HD before 1991 ( Table 1) . The structural ), and (NS4 non-structural )] and replicase (NS5, previous studies, however, underscored the fact that non-structural ) regions of the HCV. For the detection of the available serodiagnostic tests may underestimate HCV RNA, a combination of two well-established techniques the prevalence of HCV in HD patients. As possible was also available. The latter included the reverse transcrip-explanations, the prolonged viraemia before seroconvtion nested PCR (RT-PCR) and a DNA enzyme immuno-ersion to anti-HCV in HD patients [17] and their assay (DEIA, GEN-ETI-K, Sorin Biomedica, Saluggia, Italy) inability to produce antibodies towards different HCV as described previously [16 ] . The lower detection limit by antigens, as has been shown by Lok et al. [9] , probably this assay is between 10 and 102 RNA copies present in the due to their immunosuppression, have already been initial sample used for reverse transcription. The patients were evaluated twice for the detection of HCV RNA with a discussed. time interval of 6 months. At the same time, examination
The discrepancy between our findings and the previfor anti-HCV antibodies every 2 months was done in serial ous studies [11] [12] [13] [14] may be due to the serological tests serum samples of the patients. In addition, 15 anti-HCV-used for the detection of anti-HCV. In all of the positive HD patients [10 male, five female, age range 20-70 previous studies, first or second generation enzyme years, median age 55 years, duration of HD (mean±SD), immunoassays were used for the detection of anti-81.2±32.5 months] and 20 non-HD patients (10 male, 10 HCV. By contrast, in this study, two commercially female, age range 20-65 years, median age 58 years) with available third generation assays were used. The latter well-established chronic HCV infection based on clinical, assays incorporate (in addition to the antigens of the laboratory and histological assessment were used as internal previous assays) antigen encoded by the NS5 region controls in order to evaluate the accuracy of the assays used in this study.
of the HCV RNA, and contain a biochemically modified C33c recombinant protein of the HCV genome. It is believed that these enzyme immunoassays, in general,
Results
are more sensitive and specific than the previous ones [3, 18] . Another possible explanation may be genetic or other factors reflecting the known differences in our All HD patients remained anti-HCV negative by the population in general [4] [5] [6] 19, 20] . third generation enzyme immunoassays during the 6 Whatever the causes, this study provides evidence months period of the study. None of them was shown that the periodic determinations of anti-HCV remain to be viraemic by the highly specific combined assay mandatory and that routine HCV RNA detection in (RT-PCR and DEIA). By contrast, all the patients anti-HCV-negative HD patients appears rather unnewith known HCV infection tested positive for anticessary. The duration of our study (6 months) could HCV by the third generation enzyme immunoassays, be considered as short to reveal the absence of HCV whereas 13 anti-HCV-positive HD patients (86.7%) viraemia. However, taking into account our findings, and 18 non-HD patients (90%) were also viraemic by as well as the increased cost and the technical difficulty the RT-PCR.
of carrying out PCR analysis, we cannot suggest that this scientific tool should be an additional screening Table 1 . The clinical and demographic characteristics of 81 anti-test for the possible detection of viraemia in anti-HCV-HCV negative chronic haemodialysis patients negative HD patients. In our opinion, the monitoring of aminotransferase, even in low titres, every month HCV in HD patients.
Data are given as mean±SD.
